Companies / Edgewise Therapeutics, Inc. / Activity
Activity — Edgewise Therapeutics, Inc.
24 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Jan 21, 2026 | Edris Badreddin Director | Sell | Common Stock | $1.96M | -66K -77.03% | 19,820 0.02% of shares | medium |
| Mar 31, 2026 | Donovan Joanne M. Executive | Sell | Common Stock | $685.3K | -21K -68.98% | 9,597 <0.01% of shares | medium |
| Jan 21, 2026 | Edris Badreddin Director | Sell | Common Stock | $507.4K | -17K -14.17% | 104,365 0.10% of shares | medium |
| Jan 21, 2026 | Edris Badreddin Director | Sell | Common Stock | $403.0K | -14K -10.12% | 121,601 0.11% of shares | medium |
| Jan 21, 2026 | Edris Badreddin Director | Sell | Common Stock | $308.0K | -10K -10.81% | 86,297 0.08% of shares | medium |
| Mar 27, 2026 | Donovan Joanne M. Executive | Sell | Common Stock | $298.1K | -10K -37.08% | 16,332 0.02% of shares | medium |
| Jan 21, 2026 | Edris Badreddin Director | Sell | Common Stock | $223.9K | -8K -7.29% | 96,760 0.09% of shares | medium |
| Mar 27, 2026 | Donovan Joanne M. Executive | Sell | Common Stock | $208.6K | -7K -41.24% | 9,597 <0.01% of shares | medium |
| Mar 31, 2026 | Donovan Joanne M. Executive | Exercise | Common Stock | $151.1K | +21K +222.34% | 30,935 0.03% of shares | low |
| Jan 21, 2026 | Edris Badreddin Director | Exercise | Common Stock | $128.3K | +66K +108.61% | 127,686 0.12% of shares | low |
| Jan 21, 2026 | Edris Badreddin Director | Exercise | Common Stock | $20.2K | +10K +20.62% | 61,209 0.06% of shares | low |
| Jan 21, 2026 | Edris Badreddin Director | Exercise | Common Stock | $11.0K | +17K +51.44% | 50,746 0.05% of shares | low |
| Jan 21, 2026 | Edris Badreddin Director | Exercise | Common Stock | $5.4K | +8K +5.96% | 135,291 0.12% of shares | low |
| Jan 21, 2026 | Edris Badreddin Director | Exercise | Common Stock | $5.3K | +14K +69.07% | 33,510 0.03% of shares | low |
| Jan 2, 2026 | Fox Jonathan C Director | Grant | Common Stock | $0 | +473 +2.00% | 24,175 0.02% of shares | low |
| Jun 5, 2026 | Brege Laura Director | Grant | Stock Option (Right to Buy) | — | +16K | 16,377 0.02% of shares | low |
| Jun 5, 2026 | Morris Arlene Director | Grant | Stock Option (Right to Buy) | — | +16K | 16,377 0.02% of shares | low |
| Jun 5, 2026 | Thompson Peter A. Director | Grant | Stock Option (Right to Buy) | — | +16K | 16,377 0.02% of shares | low |
| Jan 21, 2026 | Edris Badreddin Director | Exercise | Stock Option (Right to Buy) | — | -14K -100.00% | 0 0.00% of shares | low |
| Jan 21, 2026 | Edris Badreddin Director | Exercise | Stock Option (Right to Buy) | — | -17K -100.00% | 0 0.00% of shares | low |
| Jan 21, 2026 | Edris Badreddin Director | Exercise | Stock Option (Right to Buy) | — | -8K -100.00% | 0 0.00% of shares | low |
| Jan 21, 2026 | Edris Badreddin Director | Exercise | Stock Option (Right to Buy) | — | -66K -100.00% | 0 0.00% of shares | low |
| Jan 21, 2026 | Edris Badreddin Director | Exercise | Stock Option (Right to Buy) | — | -10K -100.00% | 0 0.00% of shares | low |
| Mar 31, 2026 | Donovan Joanne M. Executive | Exercise | Stock Option (Right to Buy) | — | -21K -12.19% | 153,662 0.14% of shares | low |